| Margins | Shifting toward higher-margin FDF and regulated market exports. |
|---|---|
| Demand visibility | Strong visibility in Anaesthetic and Anti-diabetic chronic segments. |
| Management confidence | High focus on technical capabilities and global expansion strategy. |
Growth
Infrastructure capacity includes 1 billion tablets and capsules, targeting 40 million injection vials for high-value injectable segments.
Outlook
EU GMP certification scheduled for Q2 2026; targeting scale-up of 15+ pipeline products across diverse therapeutic categories.
Risks
Heavy dependence on R&D pipeline conversion and successful commercialization of patent-pending formulations.
Last quarter's promises, checked
Delivered
- Guided ~20% Revenue growth → delivered 18.9% (= BEAT)
- Guided 33%-35% EBITDA margin → delivered 35.5% (= BEAT)
- Guided INR 30-35cr DSM revenue → delivered INR 30-35cr (= BEAT)
Partly delivered
- Guided Contrast Media launch Q4 FY26 → delayed to H2 FY27 (= PARTIAL)
- Guided US/EU audit for Ambernath → pending auditor availability (= PARTIAL)
Missed
- Guided Q4 revenue impact INR 0 → delivered INR 10cr loss due to headwinds (= MISS)
Earnings Call Transcript filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹985.20
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Annual General Meeting
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Supriya Lifescience Legal & Regulatory
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
- Value
- ₹0.72 Cr
Supriya Lifescience Results Correction
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
Supriya Lifescience Other Announcement
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Investor Presentation: Key Takeaways
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.